Comparative Efficacy of Curative Effects of Sacubitril/Valsartan in HFpEF versus HFrEF Treatment.

ABSTRACT

Objective: This study aims to assess the differential efficacy of Sacubitril/Valsartan in treating heart failure with reduced ejection fraction (HFrEF) and preserved ejection fraction (HFpEF), thereby enhancing medication guidance for heart failure management. Methods: A retrospective cohort study was conducted, and a cohort of 89 patients, comprising 48 with HFrEF and 41 with HFpEF, treated at our hospital from February 2020 to January 2022, received Sacubitril/Valsartan. Adverse reactions were documented, and pre- and post-treatment cardiac and renal functions were evaluated. Mobility and quality of life were assessed using the 6-minute walk test (6MWT) and the Minnesota Living with Heart Failure Questionnaire (MLHFQ) . Patient outcomes were tracked for one year, measuring readmission and survival rates. Results: The study found no significant difference in the overall incidence of adverse reactions or cardiac function before and after treatment between the two groups (P > .05). However, patients with heart failure with preserved ejection fraction (HFpEF) exhibited notably greater disparities in serum creatinine and blood urea nitrogen levels, as well as in 6MWT and MLHFQ scores before and after treatment compared to those with heart failure with reduced ejection fraction (HFrEF) (P < .05). Additionally, the HFpEF group showed a lower prognostic readmission rate compared to the HFrEF group, although the difference in prognostic survival was not statistically significant (P > .05). Conclusions: Sacubitril/Valsartan demonstrates superior efficacy in improving renal function and enhancing quality of life in HFpEF patients while providing comparable prognostic benefits for HFrEF patients. This finding underscores its potential as a therapeutic foundation in the management of heart failure across ejection fraction categories.